Dengue with a morbilliform rash and a positive tourniquet test  by Feder, Henry M. et al.
CASE REPORTDengue with a morbilliform rash
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Henry M. Feder, Jr, MD,a,b Matthew Plucinski, MD,a and Diane M. Hoss, MDc
Farmington, ConnecticutINTRODUCTION
Dengue is a mosquito-borne viral infection that
should be considered in any traveler returning from
the tropics or subtropics presenting with fever and
rash.1
CASE REPORT
A 28-year-old Connecticut woman had fever
and rash 3 days after returning from the
Dominican Republic. During her trip, she ate the
food, drank the water, and suffered many
mosquito bites. The rash involved her neck, chest,
and extremities. Accompanying the rash, she had
chills, fever, headache, and malaise. She had no
arthralgias, myalgias, or diarrhea. During child-
hood, she immigrated to the United States from
the Dominican Republic. Routine immunizations
were up to date including 2 measles, mumps, and
rubella vaccinations. She had no pretravel medical
visit.
She was seen on day 4 of her illness. She was in no
distress and had a morbilliform rash on her head,
neck, trunk, and extremities. Her hemoglobin level
was 14.8 g/dL, white blood cell count was 4,200/
mm3, and platelet count was 133,000/UL. Results of a
malaria thin smear were negative.
During our patient’s visit to the Dominican
Republic, there was a dengue outbreak. This
information prompted the resident to do the
tourniquet test, which was positive (Fig 1). The
illness was mild, and only acetaminophen was
recommended. The patient’s rash, headache, chills,
and malaise resolved spontaneously over the next
week and she remained well. Dengue was
confirmed serologically—acute dengue serology
was IgM positive, and there was a greater than
4-fold increase between acute and convalescent
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422DISCUSSION
The big 3 infections associated with travel to the
developing world are dengue, malaria, and typhoid.
Recently, chikungunya (which is frequently associ-
ated with severe arthralgias) and Zika (which is
frequently associated with conjunctivitis and pruri-
tus) have become common in the tropical and
subtropical Americas. All 5 may be associated with
leukopenia and thrombocytopenia. About 25% of
patients with dengue have amorbilliform rash versus
40% to 90% of patients with chikungunya or Zika.1-7
According to the Centers for Disease Control and
Prevention, dengue fever is most commonly an acute
febrile illness defined by the presence of fever and 2
or more of the following: (1) retro-orbital or ocular
pain, (2) headache, (3) rash, (4) myalgias, (4)
arthralgias, (5) leukopenia, or (6) a positive tourni-
quet test or hemorrhagic findings.5 A tourniquet test
(which is easily performed by inflating the blood
pressure cuff halfway between the systolic and
diastolic pressures for 5 minutes), if positive, would
make dengue very likely and if negative would not
be helpful. For the diagnosis of dengue, the tourni-
quet test is specific but not sensitive. The tourniquet
test is not part of the case definition for other tropical
infections.
In studies performed in Vientiane Capital,8 Puerto
Rico,9 and Peru,10 the tourniquet test was used for
the diagnosis of dengue with specificities of 82% to
94% and sensitivities of 34% to 54%. These studies8-10
were performed before the outbreaks of chikungu-
nya and Zika. Thus, the tourniquet test has not been
studied in patients with chikungunya and Zika
infections. It is unknown why the tourniquet test is
positive in patients with dengue versus other
infections.
The clinical diagnosis of dengue can be confirmed
by reverse-transcriptase polymerase chain reaction,JAAD Case Reports 2016;2:422-3.
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Fig 1. The tourniquet test is done by inflating the blood
pressure cuff, halfway between the systolic and diastolic
pressures, for 5 minutes. A petechial rash below the cuff
(as occurred in our patient’s left antecubital fossa) defines
a positive test. A morbilliform eruption can be seen on the
arms and chest.
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serologically. During the first week of illness (during
viremia), the polymerase chain reaction or the
nonstructural protein should be positive. The IgM
antibody may be present during the first week of
illness and is usually positive in the second week.4,5
Each year, more than 50 million cases of dengue
occur inmore than 100 countries. There are 4 dengue
virus serotypes (types 1e4). The primary vector is
the Aedes aegypti mosquito, which has adapted
to the urban environment in the developing
world. Most cases of dengue are asymptomatic.
Symptomatic disease occurs 3 to 7 days after a
mosquito bite and is usually characterized by fever
and headache. Dengue lasts for a week or less, and
patients then usually recover without sequelae. An
infection with one serotype protects from
re-infection with that serotype but not the other 3
serotypes. A second infection with a new serotype
may predispose to more severe disease. Severe
dengue (the terms dengue hemorrhagic fever anddengue shock syndrome are no longer preferred) is
characterized by (1) plasma leakage with shock or
respiratory distress caused by fluid, (2) severe
bleeding, and (3) severe multiorgan dysfunction.1-5
No vaccines are available to prevent a dengue
infection (tetravalent live-attenuated vaccines are in
development). The Aedes mosquitoes are daytime
feeders, and applying a 20% to 30%DEET-containing
insect repellent effectively deters these mosquitoes
for 8 hours.11 Also, aspirin and other thrombocyte
aggregation inhibitors are best avoided for patients
with possible dengue, as these drugs may increase
bleeding complications.4,5REFERENCES
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